Novo and Roche are in line for exits from hepatitis drug developer Aligos Therapeutics, which has raised some $230m since it was founded in 2018.
Aligos Therapeutics, the US-based small molecule drug developer backed by corporates Roche and Novo, has set the terms for an initial public offering that would raise $160m at the top of its range.
The offering is set to consist of 10 million shares issued on the Nasdaq Global Market and priced between $14 and $16 each.
Founded in 2018, Aligos is developing small molecule therapeutics to treat chronic hepatitis B, the liver disease non-alcoholic steatohepatitis (NASH) and the coronavirus…
